Sign In
Buy ACIU
$2.50
+0.100 (+4.17%)
At Close: Jun 22, 2026
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
07:00am, Friday, 13'th Mar 2026
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson's
Sagimet Biosciences (NASDAQ:SGMT) vs. AC Immune (NASDAQ:ACIU) Financial Survey
01:40am, Tuesday, 17'th Feb 2026
AC Immune (NASDAQ: ACIU - Get Free Report) and Sagimet Biosciences (NASDAQ: SGMT - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two comp
AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD
02:50pm, Monday, 15'th Dec 2025
AC Immune receives a "Buy" rating, driven by positive phase 2 VacSYn trial results for ACI-7104.056 in early Parkinson's Disease. AC Immune is advancing ACI-7104.056, with upcoming FDA discussions to
AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's
12:47pm, Thursday, 11'th Dec 2025
AC Immune SA (NASDAQ: ACIU) on Thursday released interim safety and efficacy results from the Phase 2 VacSYn trial of its anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in early Parkin
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease
07:00am, Thursday, 11'th Dec 2025
The results show, for the first time, that targeting a-syn pathology with an active immunotherapy could potentially slow the rate of progression of PD.
AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates
09:55am, Tuesday, 04'th Nov 2025
AC Immune (ACIU) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to earnings of $0.06 per share a year ago.
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
07:00am, Tuesday, 04'th Nov 2025
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Sharpened investment focus on high-value assets, including three Phase 2 active immunotherapy programs and small
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline
11:01am, Tuesday, 28'th Oct 2025
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine
New Strong Sell Stocks for August 6th
08:01am, Wednesday, 06'th Aug 2025
ACIU, ABEV and ALX have been added to the Zacks Rank #5 (Strong Sell) List on August 6, 2025.
AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates
09:16am, Tuesday, 05'th Aug 2025
AC Immune (ACIU) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.25 per share a year ago.
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
07:00am, Tuesday, 05'th Aug 2025
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical
AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
11:05am, Tuesday, 29'th Jul 2025
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates
09:15am, Wednesday, 30'th Apr 2025
AC Immune (ACIU) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.21 per share a year ago.
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
07:00am, Wednesday, 30'th Apr 2025
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative disea
